InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
62,989.11
(
0.16%
)
Post# of 10489
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

cdaniel394

Send PM Follow Ignore
Followers 50
Posts 7839
Boards Moderated 0
Alias Born 11/20/2005

cdaniel394

Re: None

Wednesday, 05/18/2016 5:15:50 PM

Wednesday, May 18, 2016 5:15:50 PM

Post# of 10489
Looky here!

Conclusions: This phase I/IIa trial utilizing E39 and booster inoculations to prevent recurrence in EC and OC pts has shown the vaccine to be safe and immunogenic. These results demonstrate the potential clinical benefit of E39 at the 1000mcg dose to prevent recurrence and that boosters may sustain this effect. These promising results will be further evaluated in a larger clinical trial. Clinical trial information: NCT01580696
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up